These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 7687521

  • 21. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
    Van Horssen PJ, Preijers FW, Van Oosterhout YV, De Witte T.
    Int J Cancer; 1996 Nov 04; 68(3):378-83. PubMed ID: 8903481
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells.
    Uckun FM, Gajl-Peczalska K, Myers DE, Jaszcz W, Haissig S, Ledbetter JA.
    Blood; 1990 Dec 15; 76(12):2449-56. PubMed ID: 1702326
    [Abstract] [Full Text] [Related]

  • 24. Immunosuppression of graft rejection with idarubicin-monoclonal antibody conjugates by elimination of T cell subsets in vivo.
    Smyth MJ, Pietersz GA, McKenzie IF.
    Transplantation; 1988 Jul 15; 46(1):126-31. PubMed ID: 2899362
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G.
    Cancer Res; 1988 May 01; 48(9):2610-7. PubMed ID: 2451562
    [Abstract] [Full Text] [Related]

  • 26. A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines.
    Tsai LK, Pop LM, Liu X, Vitetta ES.
    Toxins (Basel); 2011 Apr 01; 3(4):409-19. PubMed ID: 22069716
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injections and by continuous infusion.
    Shah SA, Lambert JM, Goldmacher VS, Esber HJ, Levin JL, Chungi V, Zutshi A, Braman GM, Ariniello PD, Taylor JA.
    Int J Immunopharmacol; 1993 Aug 01; 15(6):723-36. PubMed ID: 7691767
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
    Hara H, Luo Y, Haruta Y, Seon BK.
    Cancer Res; 1988 Aug 15; 48(16):4673-80. PubMed ID: 2969282
    [Abstract] [Full Text] [Related]

  • 31. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
    Uckun FM, Myers DE, Irvin JD, Kuebelbeck VM, Finnegan D, Chelstrom LM, Houston LL.
    Leuk Lymphoma; 1993 Apr 15; 9(6):459-76. PubMed ID: 7687916
    [Abstract] [Full Text] [Related]

  • 32. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
    Hooijberg E, Sein JJ, van den Berk PC, Hart AA, van der Valk MA, Kast WM, Melief CJ, Hekman A.
    Cancer Res; 1995 Jun 15; 55(12):2627-34. PubMed ID: 7540106
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V, Engert A, Schnell R, Vitetta ES.
    Cancer Lett; 1995 Nov 27; 98(1):97-101. PubMed ID: 8529213
    [Abstract] [Full Text] [Related]

  • 35. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
    Uckun FM, Chelstrom LM, Irvin JD, Finnegan D, Gunther R, Young J, Kuebelbeck V, Myers DE, Houston LL.
    Blood; 1992 May 15; 79(10):2649-61. PubMed ID: 1375109
    [Abstract] [Full Text] [Related]

  • 36. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
    Ma D, McDevitt MR, Barendswaard E, Lai L, Curcio MJ, Pellegrini V, Brechbiel MW, Scheinberg DA.
    Leukemia; 2002 Jan 15; 16(1):60-6. PubMed ID: 11840264
    [Abstract] [Full Text] [Related]

  • 37. Evidence that an anthracycline-anti-CD8 immunoconjugate, idarubicin-anti-Ly-2.1, prolongs heart allograft survival in mice.
    Mottram PL, Pietersz GA, Smyth MJ, Purcell LJ, Clunie GJ, McKenzie IF.
    Transplantation; 1993 Mar 15; 55(3):484-90. PubMed ID: 8456465
    [Abstract] [Full Text] [Related]

  • 38. Antitumor activity of idarubicin-monoclonal antibody conjugates in a disseminated thymic lymphoma model.
    Smyth MJ, Bogdanovski M, McKenzie IF, Pietersz GA.
    Cancer Res; 1991 Jan 01; 51(1):310-7. PubMed ID: 1988093
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.